Related Experiment Video
Updated: Jul 18, 2026
09:19
Intramyocardial Transplantation of MSC-Loading Injectable Hydrogels after Myocardial Infarction in a Murine Model
Published on: September 20, 2020
Desmin 370 (Opocrin SpA/Alfa Wassermann).
1Department of Pharmacy, Tallahassee Memorial Health Care, Tallahassee, FL 32308, USA. Thertch@aol.com
Idrugs : the Investigational Drugs Journal
|August 30, 2005
Summary
Desmin 370 is an antithrombotic agent in phase III trials for deep vein thrombosis and potentially pulmonary embolism. It works by inhibiting thrombin generation and enhancing fibrinolysis.
Area of Science:
- Pharmacology
- Vascular Medicine
- Drug Development
Background:
- Deep vein thrombosis (DVT) and pulmonary embolism (PE) are significant causes of morbidity and mortality.
- Antithrombotic agents are crucial for managing and preventing these conditions.
- Current treatments have limitations, necessitating the development of novel therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy and safety of Desmin 370, an investigational antithrombotic agent.
- To explore the potential of Desmin 370 in treating deep vein thrombosis (DVT) and pulmonary embolism (PE).
Main Methods:
- Phase III clinical trials are underway to assess Desmin 370.
- The study involves evaluating Desmin 370's mechanism of action, including thrombin generation inhibition, heparin cofactor II potentiation, and local fibrinolytic effects.
Main Results:
- Desmin 370 is currently in phase III clinical trials, indicating promising preliminary data.
- The agent demonstrates antithrombotic effects through multiple mechanisms.
Conclusions:
- Desmin 370 shows potential as a novel therapeutic agent for deep vein thrombosis and pulmonary embolism.
- Further clinical research is ongoing to confirm its efficacy and safety profile.
